October 2025 BD received U.S. FDA 510(k) clearance for the BD Enteric Bacterial Panel and BD Enteric Bacterial Panel Plus for the BD COR System. The approval expands BD's molecular diagnostics portfolio with automated syndromic testing for major bacterial gastrointestinal pathogens.
August 2025 QIAGEN received U.S. FDA clearance for the QIAstat-Dx Gastrointestinal Panel 2 Mini B. The panel strengthens the company's syndromic testing portfolio by enabling rapid detection of five major bacterial causes of gastrointestinal infections in outpatient settings.
July 2025 bioMérieux expanded its BIOFIRE gastrointestinal diagnostics portfolio through new software and workflow enhancements for the BIOFIRE FilmArray system, improving laboratory efficiency and supporting faster diagnosis of enteric infections.
June 2025 Seegene expanded the commercialization of its multiplex gastrointestinal molecular diagnostic assays across Europe and Asia-Pacific, strengthening its syndromic testing portfolio for bacterial, viral, and parasitic enteric pathogens.